Wide Ranks

CGON

CG Oncology, Inc.

34.10

Top Statistics
Market Cap 2 B Forward PE -17.37 Revenue Growth 377.80 %
Current Ratio 35.32 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -18.41 Enterprise / Revenue 2581.52 Price To Sales Trailing12 Months 3371.60
Profitability
Profit Margins 0.00 % Operating Margins -65802.32 %
Balance Sheet
Total Cash 540 M Total Cash Per Share 8.00 Total Debt 296000
Total Debt To Equity 0.0550 Current Ratio 35.32 Book Value Per Share 7.95
All Measures
Short Ratio 1333.00 % Message Board Id finmb_115902660 Shares Short Prior Month 5 M
Return On Equity -0.1976 City Irvine Uuid 8a3d3fd0-b24c-3632-b8df-103b951d4052
Previous Close 33.90 First Trade Date Epoch Utc 1 B Book Value 7.95
Total Debt 296000 Volume 350844 Price To Book 4.29
Fifty Two Week Low 25.77 Total Cash Per Share 8.00 Total Revenue 684000
Shares Short Previous Month Date 1 B Target Median Price 65.50 Max Age 86400
Recommendation Mean 1.50 Sand P52 Week Change 0.3133 Operating Margins -65802.32 %
Target Mean Price 66.62 Net Income To Common -78731000 Short Percent Of Float 0.0806
Implied Shares Outstanding 67 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 547720 Average Volume10days 547720 Total Cash 540 M
Next Fiscal Year End 1 B Revenue Per Share 0.0150 Held Percent Insiders 0.0694
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 33.90 Target Low Price 51.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 36.18 Open 34.82 Free Cashflow -54284500
State CA Dividend Yield 0.00 % Return On Assets -0.1570
Time Zone Short Name EST Trailing Eps -15.87 Day Low 33.92
Address1 400 Spectrum Center Drive Shares Outstanding 67 M Price Hint 2
Target High Price 86.00 Website https://cgoncology.com 52 Week Change -0.0826
Average Volume 667131 Forward Eps -1.78 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 3460.30 % Is_sp_500 False
Regular Market Day High 34.82 Profit Margins 0.00 % Debt To Equity 0.0550
Fifty Two Week High 50.23 Day High 34.82 Shares Short 5 M
Regular Market Open 34.82 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 2581.52 Revenue Growth 377.80 % Shares Percent Shares Out 0.0798
Operating Cashflow -72696000 Currency USD Time Zone Full Name America/New_York
Market Cap 2 B Is_nasdaq_100 False Zip 92618
Quote Type EQUITY Industry Biotechnology Long Name CG Oncology, Inc.
Regular Market Day Low 33.92 Held Percent Institutions 0.9228 Current Price 34.10
Address2 Suite 2040 Enterprise To Ebitda -18.41 Financial Currency USD
Current Ratio 35.32 Industry Disp Biotechnology Number Of Analyst Opinions 8
Country United States Float Shares 45 M Two Hundred Day Average 36.16
Enterprise Value 1 B Price To Sales Trailing12 Months 3371.60 Forward PE -17.37
Regular Market Volume 350844 Ebitda -95936000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer.

The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients.

CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020.

The company was founded in 2010 and is based in Irvine, California.